Open Veils · Answer
Zimy pharma
Vimy Pharma is a strategic bet on Canadian 'pharmaceutical sovereignty' — two former Novo Nordisk Canada insiders building the domestic generic semaglutide infrastructure their former employer never created. The company sits at the intersection of supply-chain nationalism, patent-cliff exploitation, and federally-backed critical medicine manufacturing. Its TSXV reverse merger via Harmony Acquisitions Corp. is a classic capital pool vehicle used to fast-track public listing for pre-revenue biotech plays.
Evidence
- Founded in 2024 by Dave Suchon and Farris Smith — both former Novo Nordisk Canada executives — Vimy Pharma's origin story, per Alberta Doctors' Digest (September 2026), is explicitly built on watching Ozempic become Canada's best-selling drug while manufacturing profits flowed offshore.
- Vimy has filed submissions with Health Canada for generic versions of both Ozempic (type 2 diabetes) and Wegovy (weight management), per Dealroom News (November 2026).
- On November 12, 2026, the company completed its qualifying transaction via a three-cornered amalgamation with Harmony Acquisitions Corp., listing on the TSXV (per Newsfile Corp.).
- Their stated mission is 'pharmaceutical sovereignty': Canadian ownership, Canadian R&D, Canadian production.
- Production is planned through Applied Pharmaceutical Innovation (API), an Edmonton-based non-profit, at its Critical Medicines Production Centre — part of a roughly $200-million federal Canadian Critical Drug Initiative that explicitly lists semaglutide as a critical medicine.
